Phase Space AI

Xylem

XYL · investment memo

Valuation margin
demonstrated − required CAGR
-18.0%
Required CAGR
19.3%
Demonstrated
1.3%
Terminal margin
16.0%
Exit multiple
9.6x
Company state
A

Risk & exit

Four distinct questions, one field each. A price is not a thesis: the trigger below forces a re-underwrite and freezes further purchases — it is never an automatic sell.

Risk trigger
12% below the memo price
$102.63
Forward E[R]
vs a 0% floor
+31.2%

A daily close below $102.63 triggers a mandatory re-underwrite and freezes further purchases. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.

Thesis-invalidation conditions

Not stated. This name has no falsifiable invalidation conditions on file, so it cannot be risk-monitored. That is a gap in the research, not a clean bill of health — recorded rather than hidden.

Impairment case

1. The Q2'26 orders spike is unexplained and unaudited. $850m of organic orders in the lowest-visibility, second-lowest-margin segment, with no narrative, no named contract and no stated conversion period. If it is one multi-decade municipal operations contract, its revenue contribution per year is small and its margin is low-teens. 2. Organic revenue growth is 0.5–1.3% and Measurement & Control is shrinking (−1.4% organic revenue, −1.6% total orders). M&C is 21.7% of revenue at a 12.4% margin. 3. The margin expansion is half non-repeating. 180bp of the 340bp came from lower charges. 4. The bu

Documents

XYL Catalyst Calendar XYL Financial Model Notes XYL Research XYL Trade Construction XYL Valuation